Skip to main content
Vetoquinol SA logo

Vetoquinol SA — Investor Relations & Filings

Ticker · VETO ISIN · FR0004186856 LEI · 969500YP0AETQIK48R39 PA Manufacturing
Open in API
Filings indexed 299 across all filing types
Latest filing 2021-01-21 Earnings Release
Country FR France
Listing PA VETO

About Vetoquinol SA

https://www.vetoquinol.com/en

Vetoquinol SA is a global animal health company that researches, develops, produces, and markets veterinary medicines and non-medicinal products. The company provides solutions for both companion animals (cats and dogs) and livestock (cattle and pigs). Its product portfolio addresses a wide range of therapeutic areas, including mobility, dermatology, anti-parasitics, antibiotics, internal medicine, and behavior management. Founded in 1933, the independent, family-owned business focuses on innovation and maintaining a close relationship with veterinary professionals to support animal well-being.

Recent filings

Filing Released Lang Actions
Inside Information / Information on annual revenues
Earnings Release Classification · 100% confidence The document is a press release dated January 21st, 2021, announcing the company's 2020 sales figures (€427.5M, up 8.0% as reported). It provides key financial highlights for the full year and the fourth quarter, includes commentary from the CEO, and mentions that the audit of the financial statements is in progress. This format—a brief, high-level announcement of period results before the full official filing—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) nor the detailed Interim Report (IR), as it focuses on sales highlights and explicitly states the full Annual Results are due on April 1st, 2021. It is too specific for a general Regulatory Filing (RNS) and is clearly a results announcement. FY 2020
2021-01-21 English
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 99% confidence The document text explicitly reports the 'CHIFFRE D'AFFAIRES 2020' (2020 Revenue) figures, including quarterly breakdowns and year-end results, comparing them to the previous year (2019). It contains detailed financial performance metrics, management commentary on the full year's results, and a table summarizing quarterly performance for the full fiscal year 2020. The text also mentions that the 'audit des comptes de Vetoquinol est en cours' (audit of accounts is in progress) and announces the 'Résultats annuels 2020' (Annual Results 2020) publication date for April 1, 2021. Since this document provides the comprehensive financial results for the full fiscal year 2020, it aligns best with the definition of an Annual Report (10-K), even though it is presented as a press release summarizing the year's performance, which often precedes or is the primary content of the 10-K filing. Given the comprehensive nature of the full-year financial data presented, 10-K is the most appropriate classification over a simple Earnings Release (ER) or Interim Report (IR). FY 2020
2021-01-21 French
Inside Information / Operations of the issuer (acquisitions, sales...)
M&A Activity Classification · 99% confidence The document is titled 'PRESS RELEASE' and details an expansion of a collaboration between two companies (Orion Animal Health and Vetoquinol) involving new distribution agreements for specific veterinary products (Clevor®, Drontal®, Profender®). It includes quotes from executives, contact information for Investor Relations, and brief 'ABOUT' sections for both companies. This content structure is typical of a corporate announcement intended for immediate public dissemination, often related to business development or strategic updates, rather than a formal regulatory filing like a 10-K, an earnings release (ER) focusing on financial figures, or a detailed management discussion (MDA). Since it announces business developments and strategic partnerships, it fits best under the general category of corporate news. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release that doesn't fit a more specific operational or financial category, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. Since it is a general business update announcement, RNS is the best fit as a catch-all for non-standard, yet important, corporate news releases.
2021-01-18 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Regulatory Filings Classification · 95% confidence The document is titled 'COMMUNIQUÉ DE PRESSE' (Press Release) and details an expansion of a distribution collaboration between Orion Animal Health and Vetoquinol regarding specific veterinary products (Clevor®, Drontal®, Profender®). This type of announcement, detailing business agreements, partnerships, or operational updates, is typically classified as a general regulatory announcement or press release that doesn't fit into the highly specific financial report categories (like 10-K, ER, IR). Furthermore, the document explicitly states: 'Prochaine publication : Chiffre d'affaires annuel 2020, le 21 janvier 2021 après fermeture de la Bourse' (Next publication: Annual revenue 2020, on January 21, 2021 after market close). This confirms the current document is NOT the Annual Report (10-K) or Earnings Release (ER), but rather a preceding announcement. Given its nature as a business update/press release that doesn't fit other specific codes (like M&A, CAP, DIRS), the most appropriate fallback category is Regulatory Filings (RNS). The document length (4532 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2021-01-18 French
Inside Information / Operations of the issuer (acquisitions, sales...)
M&A Activity Classification · 99% confidence The document is a press release dated January 11th, 2021, announcing a specific corporate action: Vetoquinol's acquisition of the Australian rights for Drontal® and Profender® product families from Elanco Animal Health. This type of announcement, detailing a merger, acquisition, or takeover proposal/completion, falls under the M&A Activity category. The document is short and clearly communicates a transaction, fitting the definition for TAR (Merger/Takeover Activity). It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific strategic transaction.
2021-01-11 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Regulatory Filings Classification · 100% confidence The document is a press release dated January 11, 2021, announcing that Vetoquinol has acquired the Australian rights for the Drontal® and Profender® product lines from Elanco Animal Health. This is a specific corporate action related to business development, mergers, or acquisitions (M&A). The content details the assets acquired and includes a quote from the CEO. This fits the definition of M&A Activity (TAR). It is not a standard regulatory filing like 10-K or ER, nor is it a general announcement of a future report (RPA).
2021-01-11 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.